Early research (Phase 1)Study completedNCT02115347
What this trial is testing
Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
Who this might be right for
Type 2 Diabetes MellitusHepatic Impairment
Merck Sharp & Dohme LLC 16